Rectal Cancer. Malignant neoplasm of rectum
Conditions
Interventions
Intervention 1: Intervention group: Oral aspirin 100 mg daily concurrent with standard chemoradiotherapy. Intervention 2: Control group: Standard chemoradiotherapy.
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients with pathologically proven rectal adenocarcinoma stage 2-3 rectal cancer (i.e. T3-4 or N+) The patient is a candidate for neoadjuvant chemoradiotherapy. ECOG Performance Status Score=0-2
Exclusion criteria
Exclusion criteria: A patient with distant metastasis on admission Patients who have received any prior treatment for another malignancy. Patients with any thromboembolic or hemorrhagic events within 6 months before registration Active gastrointestinal bleeding Patients with malabsorption syndrome or swallowing disorders Concomitant familial polyposis Associated synchronous colon adenocarcinoma Pregnancy or any contraindication conditions for chemoradiotherapy Patients who already receive aspirin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pathological Complete Response. Timepoint: Six to ten weeks after the end of chemoradiotherapy. Method of measurement: According to the pathology report of surgery. | — |
Secondary
| Measure | Time frame |
|---|---|
| Tumor Down Staging. Timepoint: Six to ten weeks after the end of chemoradiotherapy. Method of measurement: According to the pathology report of surgery. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactKambiz Novin
Iran University of Medical Sciences
Outcome results
None listed